文献速递临床试验与 GCP基础与转化研究组学、生物样本库与精准医学

伴非典型特征抑郁症的个体化诊断与治疗研究(iDoT-AFD):随机临床试验与预后研究的研究方案

A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study.
PubMed 文献 · Trials · 2023-05-04

iDoT-AFD是一项多中心、前瞻性、开放标签研究,包含12周随机对照试验及随访至4年或研究终点的持续随访。研究纳入480例伴非典型特征抑郁症(AFD)患者(每治疗组120例)、100例双相障碍(BD)患者和100例健康对照,采集临床特征、认知功能、犬尿氨酸通路代谢组学及多模态磁共振成像数据,旨在识别AFD、寻找优化治疗策略并构建转相为BD的风险预警模型。

要点

  • 研究纳入AFD患者480例、BD患者100例和健康对照100例,随访至4年或转相为BD。
  • AFD患者随机分入四组治疗12周:单用SSRI或SNRI、SSRI/SNRI联合心境稳定剂、SSRI/SNRI联合喹硫平(≥150 mg/日)、常规治疗(TAU)。
  • 研究探索AFD诊断与预后相关的临床及生物学标志物,为AFD临床指南提供证据。

核心结论

  • iDoT-AFD研究探索AFD诊断、治疗和预后的临床与生物学标志物,并进一步为AFD临床指南提供证据。

研究设计与样本

  • 多中心、前瞻性、开放标签研究,包含12周随机对照试验及随访至4年或研究终点的持续随访。
  • 纳入480例AFD患者(每治疗组120例)、100例BD患者和100例健康对照。
  • 采集多维信息,包括临床特征、认知功能、犬尿氨酸通路代谢组学和多模态磁共振成像数据。

主要发现

  • 采用多变量信息学分析从首發和复发非典型抑郁、BD患者及健康对照中识别AFD患者。
  • AFD患者随机分配至四组治疗并随访12周以寻找优化治疗策略。
  • AFD患者随访至4年或转相为BD,以探索从非典型抑郁转相为BD的危险因素并最终构建转相为BD的风险预警模型。
  • 首次入组时间为2019年8月。

关键数值与推荐

  • AFD患者随机分配至四组之一:单用选择性5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI);SSRI/SNRI联合心境稳定剂;SSRI/SNRI联合喹硫平(≥150 mg/日);常规治疗(TAU)。
  • AFD患者每治疗组120例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major depressive disorder (MDD) with atypical features, namely depression with atypical features (AFD), is one of the most common clinical specifiers of MDD, closely associated with bipolar disorder (BD). However, there is still a lack of clinical guidelines for the diagnosis, treatment, and prognosis of AFD. Our study mainly focuses on three issues about how to identify AFD, what is the appropriate individualized treatment for AFD, and what are the predictive biomarkers of conversion to BD. METHODS: The Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD) is a multicenter, prospective, open-label study consisting of a 12-week randomized controlled trial (RCT) and a continued follow-up until 4 years or reaching the study endpoint. It is enrolling 480 patients with AFD (120 per treatment arm), 100 patients with BD, and 100 healthy controls (HC). Multivariate dimension information is collected including clinical features, cognitive function, kynurenine pathway metabolomics, and multimodal magnetic resonance imaging (MRI) data. Firstly, multivariate informatics analyses are performed to recognize patients with AFD from participants including the first-episode and recurrent atypical depression, patients with BD, and patients with HC. Secondly, patients with atypical depression are randomly allocated to one of the four treatment groups including "single application of selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI)", "SSRI/SNRI combined with mood stabilizer," "SSRI/SNRI combined with quetiapine (≥ 150 mg/day)," or "treatment as usual (TAU)" and then followed up 12 weeks to find out the optimized treatment strategies. Thirdly, patients with atypical depression are followed up until 4 years or switching to BD, to explore the risk factors of conversion from atypical depression to BD and eventually build the risk warning model of conversion to BD. DISCUSSION: The first enrolment was in August 2019. The iDoT-AFD study explores the clinical and biological markers for the diagnosis, treatment, and prognosis of AFD and further provides evidence for clinical guidelines of AFD. TRIAL REGISTRATION: ClinicalTrials.gov NCT04209166. Registered on December 19, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhou R, Zhang H, He S, et al. A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study. Trials. 2023. PMID: 37143128. doi:10.1186/s13063-023-07317-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。